Drugs in Dev. Ophthalmology
Phase II
Israel 
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Details : AZR-MD-001 harnesses the power of selenium sulfide (SeS2) in an easy-to-use ophthalmic ointment preparation applied directly to the meibomian glands on the eye lid.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AZR-MD-001
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Avania
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Contact Lens Discomfort (CLD)
Details : AZR-MD-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Contact Lens Discomfort.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : AZR-MD-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Avania
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TRS01,Adapalene
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company received important feedback on its trial design and program for its TRS01 Phase 3 program in uveitis, including feedback on its nonclinical and CMC plans supporting submission of a New Drug Application (NDA) in the U.S.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : TRS01,Adapalene
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CSF-1
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Bluestem Capital
Deal Size : $30.0 million
Deal Type : Series C Financing
Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia
Details : Proceeds from the financing will be used to advance Orasis’ lead eye drop candidate for the treatment of presbyopia symptoms through completion of its Phase 3 clinical trials.
Product Name : PresbiDrops
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 10, 2020
Lead Product(s) : CSF-1
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Bluestem Capital
Deal Size : $30.0 million
Deal Type : Series C Financing
Lead Product(s) : AZR-MD-001
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Avania
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)
Details : AZR-MD-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Meibomian Gland Dysfunction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 18, 2020
Lead Product(s) : AZR-MD-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Avania
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AZR-MD-001
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : University of New South Wales
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZR-MD-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Meibomian Gland Dysfunction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 03, 2019
Lead Product(s) : AZR-MD-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : University of New South Wales
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colony Stimulating Factor 1
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Colony Stimulating Factor 1 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Presbyopia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 21, 2019
Lead Product(s) : Colony Stimulating Factor 1
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AZR-MD-001
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Syneos Health | Cliantha Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZR-MD-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Meibomian Gland Dysfunction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2018
Lead Product(s) : AZR-MD-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Syneos Health | Cliantha Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CSF-1
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects
Details : PresbiDrops (CSF-1) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Presbyopia.
Product Name : PresbiDrops
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 17, 2016
Lead Product(s) : CSF-1
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CSF-1
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia
Details : PresbiDrops (CSF-1) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Presbyopia.
Product Name : PresbiDrops
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 20, 2016
Lead Product(s) : CSF-1
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
